KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Average (2016 - 2025)

Rigel Pharmaceuticals has reported Equity Average over the past 15 years, most recently at $254.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 4586.16% year-over-year to $254.5 million; the TTM value through Dec 2025 reached $254.5 million, up 4586.16%, while the annual FY2025 figure was $197.4 million, 1656.9% up from the prior year.
  • Equity Average for Q4 2025 was $254.5 million at Rigel Pharmaceuticals, up from $99.8 million in the prior quarter.
  • Over five years, Equity Average peaked at $254.5 million in Q4 2025 and troughed at -$30.8 million in Q2 2024.
  • A 5-year average of $22.1 million and a median of -$2.1 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: plummeted 1778.05% in 2023 and later soared 4586.16% in 2025.
  • Year by year, Equity Average stood at $40.0 million in 2021, then plummeted by 141.79% to -$16.7 million in 2022, then crashed by 80.8% to -$30.2 million in 2023, then skyrocketed by 81.24% to -$5.7 million in 2024, then soared by 4586.16% to $254.5 million in 2025.
  • Business Quant data shows Equity Average for RIGL at $254.5 million in Q4 2025, $99.8 million in Q3 2025, and $50.3 million in Q2 2025.